Science News

We are living in a world that is global and exponential. Technology is taking things that used to be scarce and making them abundant--and these forces are reshaping the fields of medicine and healthcare in completely nov...

What are the limits of human perception? Take a second and concentrate on your surroundings: the subtle flickering of your laptop screen, the faint whiff of lingering coffee, the muffled sounds of traffic, the warm touch...

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers re...

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 stu...

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.

Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.

The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.